Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab.
The potential impact of different SNPs of VEGF/VEGFR pathway on the clinical outcome of mCRC patients receiving bev-containing regimens has been investigated in retrospective experiences with contrasting results. We previously reported the association of VEGFA rs833061 C/T variants with PFS in metas...
Main Authors: | Fotios Loupakis, Chiara Cremolini, Dongyun Yang, Lisa Salvatore, Wu Zhang, Takeru Wakatsuki, Pierre Bohanes, Marta Schirripa, Leonor Benhaim, Sara Lonardi, Carlotta Antoniotti, Giuseppe Aprile, Francesco Graziano, Annamaria Ruzzo, Sara Lucchesi, Monica Ronzoni, Ferdinando De Vita, Giuseppe Tonini, Alfredo Falcone, Heinz-Josef Lenz |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3701556?pdf=render |
Similar Items
-
Retrospective exploratory analysis of <it>VEGF </it>polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer
by: Manzoni Mariangela, et al.
Published: (2011-06-01) -
The Winding Roadmap of Biomarkers Toward Clinic: Lessons from Predictors of Resistance to Anti-EGFRs in Metastatic Colorectal Cancer
by: Carlotta Antoniotti, et al.
Published: (2018-08-01) -
Balanitis associated with FOLFIRI chemotherapy
by: Goran Micevic, PhD, et al.
Published: (2018-01-01) -
TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group
by: Chiara Cremolini, et al.
Published: (2017-06-01) -
Single Nucleotide Polymorphisms in MiRNA Binding Sites of Nucleotide Excision Repair-Related Genes Predict Clinical Benefit of Oxaliplatin in FOLFOXIRI Plus Bevacizumab: Analysis of the TRIBE Trial
by: Mitsukuni Suenaga, et al.
Published: (2020-06-01)